Stakeholder, Expert Endorsements Grow for Finance Committee Prescription Drug Legislation
“ARM applauds the Senate Finance Committee’s proposal to encourage the adoption of value-based pricing models for the reimbursement of gene therapies in Medicaid. This bipartisan effort is an important first step…”
The Alliance for Regenerative Medicine (ARM) is an international organization that advocates on issues relating to regenerative medicine and advanced therapies including gene therapy, cell therapy and tissue engineering.
“As a community of 135 ally organizations and more than 400,000 beneficiaries, we are encouraged by the Committee’s efforts to bring those protections to individuals with high prescription drug costs.”
The Better Medicare Alliance (BMA) advocates for Medicare Advantage and quality health care on behalf of seniors.
“The Chairman’s Mark contains very important and valuable drug cost protections for seniors and people with disabilities to ensure they have access to the medications they need.”
The Blue Cross Blue Shield Association is a federation of independent organizations that provide health coverage across the country.
“On behalf of the millions of families who are struggling, we urge you to pass this legislation through committee, continue to strengthen it… Never forget you have your constituents’ strong support in these efforts.”
Families USA, a nonprofit advocacy organization, seeks to advance high-quality, affordable health care for all.
“On behalf of the 25 to 30 million Americans with one of the over 7,000 known rare diseases, the National Organization for Rare Disorders (NORD) applauds the Committee for its efforts to drive meaningful, bipartisan drug pricing reform.”
The National Organization for Rare Disorders (NORD) is a patient advocacy organization dedicated to individuals with rare diseases.
*These endorsements follow sweeping support announced yesterday by stakeholders, experts and the Trump administration.
Next Article Previous Article